{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056223","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.953476+00:00","generated_at":"2026-06-02T07:07:49.600738+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvalent reports Q1 net loss of $44.5M; cash $691.8M; pipeline milestones on track","bullets":["Q1 2024 net loss of $44.5M; R&D expense $38.6M, G&A $14.0M.","Cash, cash equivalents and marketable securities $691.8M as of March 31, 2024; runway into 2027.","Updated data from ARROS-1 (ROS1) and ALKOVE-1 (ALK) trials expected at a medical meeting in H2 2024.","Phase 1 trial for HER2 program (NVL-330) expected to initiate in 2024.","Plans to outline front-line development strategy for ALK program in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056223","json":"https://secwatch.observer/filing/0000950170-24-056223.json","markdown":"https://secwatch.observer/filing/0000950170-24-056223.md","text":"https://secwatch.observer/filing/0000950170-24-056223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024056223/0000950170-24-056223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024056223/nuvl-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:07:49.600738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c128a9ad999da89c3bd88cf8a224e9d665b5679","claim":"Nuvalent, Inc. reported first quarter 2024 results: net income Net loss was $44.5 million for the first quarter of 2024..","evidence_excerpt":"Net loss was $44.5 million for the first quarter of 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024056223/0000950170-24-056223-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Net income","value":"Net loss was $44.5 million for the first quarter of 2024."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}